Ipamorelin: A Research Overview

Introduction

Ipamorelin (developmental designation NNC 26-0161) is a synthetic pentapeptide classified as a growth hormone secretagogue (GHS) and a selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a) — the same receptor that mediates the effects of the endogenous peptide ghrelin. Discovered by researchers at Novo Nordisk A/S in the late 1990s, ipamorelin was distinguished from earlier compounds in its class by a notably selective hormonal profile observed in preclinical studies, and was the subject of preclinical and early clinical investigation spanning pituitary biology, bone physiology, gastrointestinal research, and pharmacokinetics. This article provides an educational reference overview of ipamorelin's chemical identity, pharmacological classification, discovery history, and regulatory context.

Background

The research program that produced ipamorelin grew from two decades of work on synthetic peptides capable of stimulating pituitary growth hormone (GH) release through pathways distinct from growth hormone-releasing hormone (GHRH). The first generation of GH-releasing peptides — including GHRP-6, GHRP-2, and hexarelin — demonstrated potent GH-releasing activity in research models but also co-stimulated the release of adrenocorticotropic hormone (ACTH), cortisol, and prolactin, a profile that complicated their pharmacological characterization.

Raun and colleagues at Novo Nordisk reported in 1998 that ipamorelin represented a meaningful departure from this pattern. In both in vitro and in vivo models, the compound displayed GH-releasing potency comparable to GHRP-6 while exhibiting a markedly more selective hormonal profile — leading the authors to describe it as "the first selective growth hormone secretagogue" [1]. This selectivity distinguished ipamorelin from its predecessors and provided a pharmacological basis for continued investigation across multiple research domains.

Chemistry and Structure

Ipamorelin is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its structural components include an α-aminoisobutyric acid (Aib) residue at the N-terminus, which confers conformational rigidity; a histidine residue; the non-natural amino acid D-2-naphthylalanine (D-2-Nal); D-phenylalanine; and a C-terminal lysine-amide. The molecular formula is C₃₈H₄₉N₉O₅, with a molecular weight of approximately 711.9 daltons.

The ipamorelin sequence was derived through structure-activity relationship (SAR) work beginning from the GHRP-1 scaffold. Raun et al. reported that ipamorelin emerged from a series of compounds lacking the central dipeptide Ala-Trp of GHRP-1, and that its structural modifications were associated with the improved selectivity profile observed in preclinical studies [1]. A companion medicinal chemistry report by Ankersen and colleagues (1998) extended this SAR program, reporting that the ipamorelin template anchored a new series of highly potent GHS compounds with varied physicochemical properties [2].

The compound carries no glycosylation and no fatty-acid modification, distinguishing it structurally from later-generation ghrelin mimetics that employ lipidation strategies to extend plasma half-life.

Pharmacological Classification

Ipamorelin is classified as a synthetic GHS-R1a agonist within the broader pharmacological class of growth hormone secretagogues. GHS-R1a — initially designated the GH secretagogue receptor and later confirmed as the cognate receptor for ghrelin (identified in 1999) — is a G protein-coupled receptor (GPCR) that signals primarily through the Gαq/phospholipase C pathway [3].

Within this pharmacological class, ipamorelin occupies a specific niche as a peptidyl, selective agonist. The foundational 1998 study by Raun et al. reported that ipamorelin did not stimulate ACTH or cortisol at concentrations more than 200-fold above its median effective dose (ED₅₀) for GH release in vivo in conscious swine, and did not significantly alter FSH, LH, prolactin, or TSH levels [1]. The receptor pharmacology underlying this selectivity has been attributed in the broader literature to differences in how ipamorelin engages downstream signaling cascades relative to earlier GHRPs, though the precise molecular basis continues to be investigated.

Ipamorelin should be distinguished from non-peptidyl GHS compounds (peptidomimetic secretagogues) and from GHRH analogs such as CJC-1295, which operate through the distinct GHRH receptor rather than GHS-R1a.

Discovery History

Ipamorelin was identified and characterized within the GH secretagogue research program at Novo Nordisk A/S in Måløv, Denmark. The principal investigators credited in the foundational 1998 report were K. Raun, B.S. Hansen, N.L. Johansen, H. Thøgersen, K. Madsen, M. Ankersen, and P.H. Andersen [1]. The compound's discovery occurred during a period of broad pharmaceutical industry activity — spanning Merck Research Laboratories, Novo Nordisk, and other organizations — directed at identifying synthetic GHS compounds suitable for clinical investigation.

Following the identification of ghrelin as the endogenous GHS-R1a ligand by Kojima and colleagues in 1999, the scientific framing of ipamorelin and related compounds shifted from "GHRP-like agonists" to "ghrelin receptor agonists," providing additional physiological context for understanding the GHS-R1a target. Research after 1999 extended the ipamorelin profile into bone metabolism [4], gastrointestinal physiology [5, 6], somatotroph biology [7], and pharmacokinetics [8] — all areas summarized in companion articles in this library.

Regulatory Status

Ipamorelin has not received marketing approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any therapeutic indication in humans. Research-grade ipamorelin from SpartaLabs is supplied as a research-use-only material with batch-specific analytical documentation.

Clinical investigation of ipamorelin progressed to phase 2 trials for postoperative ileus, sponsored by Helsinn Therapeutics (U.S.), Inc. (ClinicalTrials.gov identifiers NCT00672074 and NCT01280344). A published proof-of-concept phase 2 trial by Beck and colleagues (2014) enrolled 117 patients undergoing bowel resection and reported that ipamorelin was well tolerated, with median time to tolerating a solid meal of 25.3 hours (ipamorelin) versus 32.6 hours (placebo); this difference did not achieve statistical significance on the primary composite endpoint in this proof-of-concept cohort [9]. The trial contributed human safety and tolerability data to the scientific record and informed subsequent understanding of ghrelin receptor agonist pharmacology in the clinical setting.

Regarding pharmaceutical compounding, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed ipamorelin in proceedings including the October 2024 PCAC meeting under Section 503A of the Federal Food, Drug, and Cosmetic Act. The compound does not appear on the United States Pharmacopeia (USP) or National Formulary (NF) and is not an active ingredient in any FDA-approved drug product. Ipamorelin is available from research suppliers as a research-use-only (RUO) material.

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822. DOI: 10.1530/eje.0.1390552

2. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem. 1998;41(19):3699-704. PMID: 9733495. DOI: 10.1021/jm9801962

3. Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014;15(3):4837-55. PMID: 24651458. DOI: 10.3390/ijms15034837

4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343. DOI: 10.1054/ghir.1999.9998

5. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6. PMID: 19289567.

6. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-55. PMID: 27186127. DOI: 10.2147/JEP.S35396

7. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-14. PMID: 12168778. DOI: 10.14670/HH-17.707

8. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-92. PMID: 9879640. DOI: 10.1080/004982598238976

9. Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID: 25331030. DOI: 10.1007/s00384-014-2030-8